ECDA/ECDAW receives Nasdaq delisting warning; appeal to stay action
Rhea-AI Filing Summary
ECD Automotive Design, Inc. received a Nasdaq notice stating its common stock closed below $1 per share for a 30-business-day period and therefore failed to satisfy Listing Rule 5550(a)(2). The company was given a compliance period that ended on August 4, 2025 and did not regain the required bid price; it also does not meet the minimum stockholders' equity requirements for initial listing and its warrants are subject to delisting under Nasdaq rules.
On August 6, 2025 Nasdaq issued an additional notice saying trading will be suspended at the opening of business on August 15, 2025 and a Form 25-NSE will be filed unless the company requests an appeal by August 13, 2025. The company intends to timely request an appeal, and that hearing request will stay any suspension or delisting action pending the Panel's decision.
Positive
- Company intends to appeal the Nasdaq determination, and a hearing request will stay suspension or delisting pending review
- Trading and listing removal are not immediate while the company pursues the appeals process
Negative
- Failed to regain compliance with Nasdaq Listing Rule 5550(a)(2) after the 180-day cure period ended on August 4, 2025
- Ineligible for a second 180-day period, limiting available cure options under Nasdaq procedures
- Does not meet minimum stockholders' equity requirements for initial listing, an additional independent ground for delisting
- Warrants are subject to delisting pursuant to Listing Rule 5560(a), putting both equity and derivative securities at risk
- Immediate suspension scheduled at the opening of business on August 15, 2025 unless an appeal is filed by August 13, 2025
Insights
TL;DR This is a material negative: delisting risk may sharply reduce liquidity and market access if not resolved.
The Nasdaq notices confirm the company failed to cure a sustained bid-price deficiency and also lacks required stockholders' equity for initial listing. Nasdaq's timeline creates near-term execution risk: without a successful appeal or rapid compliance, public trading will be suspended and Form 25-NSE filed, which removes the securities from Nasdaq registration. Even with an appeal stay, uncertainty can reduce liquidity, impair capital-raising ability, and depress valuations until resolved.
TL;DR Procedural appeal can delay delisting, but the company faces significant listing-standards hurdles.
The company retains the procedural right to request review by the Nasdaq Hearings Panel; such a request will stay suspension or delisting pending the hearing. However, Nasdaq cited both price-based noncompliance and insufficient stockholders' equity, and the filing notes the company is ineligible for a second 180-day cure period. Remediation will require either restoring the bid price or meeting equity standards, or persuading the Panel of mitigating factors to avoid removal.